Pérez ME, Barberá R, Domínguez F, Otero O, Gutiérrez M, Falero G, Reyes G, Sotolongo F, Sierra G

Language: English
References: 16
Page: 6-10
PDF size: 160.52 Kb.

ABSTRACT

Neisseria meningitidis isolates are conventionally classified by serosubtyping that characterizes the reactivities of the PorA outer membrane protein variable-region epitopes with monoclonal antibodies. Porins are outer membrane proteins (OMPs) of N. meningitidis serogroup B and have attracted study principally for two reasons: their use in the classification of meningococcal isolates into serotype and subtype and as potential components of vaccines against this important pathogen. New murine hybridomas, secreting specific monoclonal antibodies against PorA serotype P1.4 of N. meningitidis serogroup B, were generated using conventional hybridoma procedures. The monoclonal antibodies obtained were characterized by Western blot and whole cell ELISA, using reference strains from different N. meningitidis serotypes and subtypes. All monoclonal antibodies belong to isotype IgG1. Others hybridomas producing MAbs against PorB and FrpB were also obtained.

REFERENCES

1. TrotterCL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006;134:556-66.

2. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcemia and Neisseria meningitidis. Lancet 2007;369:2196-210.

3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27S:B51-63.

4. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27S:B112-6.

5. Oomen CJ, Hoogerhout P, Kuipers B, Vidarsson G, van Alphen L, Gros P. Crystal Structure of an Anti-meningococcal Subtype P1.4 PorA Antibody Provides Basis for Peptide–Vaccine Design. Journal of Molecular Biology 2005;351:1070-80.

6. Huergo CC, Sierra GV, Gutiérrez MM, Biset G, García L, Puentes G, et al. Centro Nacional de Biopreparados, assignee. Method of producing Neisseria meningitidis B vaccine. US Patent 5,597,572. 1997, Jan 28.

7. Gavilondo JV. Anticuerpos Monoclonales. La Habana: Elfos Scientiae 1995. p. 46-9.

8. Tu YY, James PF, Goldenberg DM: Temperature affects binding of murine monoclonal antibodies to proteins. A. J Immunol Methods 1998;109:43-7.

9. Laemmli UK. Cleavage of structural proteins during the assembly of bacteriophage T4. Nature 1990;227:680-5.

10. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from poliacrylamide gels to nitrocellulose sheets procedure and some applications. Proc Natl Acad Sci. USA. 1979;76:4350-4.

11. Wedege E, Dalseg R, Caugant DA, Poolman JT, Frholm LO. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J Med Microbiol 1993;38:23- 8.

12. Pérez ME, Barberá R, Domínguez F, Otero O, Gutiérrez M, Falero G, et al. Development and characterization of murine monoclonal antibody specific for the P1.15 PorA proteins from a Cuban vaccine strain B:4,7:P1.19,15 of Neisseria meningitidis. Hibridoma 2006;25:243-7.

13. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31:3-14.

14. Sadarangani M, Pollard A. Serogroup B meningococcal vaccines –an unfinished story. Lancet Infect Dis 2010;10:112- 24.

15. Climent Y, Urwin R, Yero D, Martínez I, Martín A, Sotolongo F, et al. The genetic structure of Neisseria meningitidis populations in Cuba before and after the introduction of a serogroup BC vaccine. Infection, Genetics and Evolution 2010;10:546-54.

16. Climent Y, Yero D, Martínez I, Martín A. Jolley KA, Sotolongo F, et al. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. Journal of Clinical Microbiology 2010;48:802- 10.